WP
SUPN icon

Woodline Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Woodline Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.9M Buy
708,276
+259,280
+58% +$12.5M 0.1% 264
2026
Q1 		$23.2M Buy
+448,996
New +$22.9M 0.09% 306
2025
Q4 		– Sell
-1,263,811
Closed -$60.4M – 1115
2025
Q3 		$60.4M Buy
1,263,811
+490,835
+63% +$19.8M 0.28% 78
2025
Q2 		$24.4M Buy
+772,976
New +$24.8M 0.13% 236
2025
Q1 		– Sell
-423,828
Closed -$15.3M – 1024
2024
Q4 		$15.3M Buy
423,828
+235,257
+125% +$8.28M 0.1% 261
2024
Q3 		$5.88M Buy
+188,571
New +$5.89M 0.05% 371
2024
Q2 		– Sell
-1,291,291
Closed -$44M – 662
2024
Q1 		$44M Buy
+1,291,291
New +$38.4M 0.41% 68
2023
Q1 		– Sell
-105,878
Closed -$3.78M – 768
2022
Q4 		$3.78M Sell
105,878
-687,889
-87% -$23.9M 0.05% 361
2022
Q3 		$26.9M Buy
793,767
+225,188
+40% +$7.33M 0.38% 76
2022
Q2 		$16.4M Buy
568,579
+83,167
+17% +$2.38M 0.25% 123
2022
Q1 		$15.7M Buy
+485,412
New +$14.9M 0.25% 122
2021
Q4 		– Sell
-53,915
Closed -$1.44M – 783
2021
Q3 		$1.44M Buy
+53,915
New +$1.45M 0.02% 470

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Woodline Partners's SUPN Position: Q2 2026 in Review

Woodline Partners increased its Supernus Pharmaceuticals (SUPN) stake by 58% in Q2 2026, buying an estimated $12.5M and bringing the position to 708,276 shares worth $32.9M. The position accounts for 0.1% of the portfolio, ranked #264.

Woodline Partners first reported a position in SUPN in Q3 2021 and has held it in 12 quarters since. The position peaked at $60.4M in Q3 2025. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Woodline Partners held 708,276 shares of Supernus Pharmaceuticals worth $32.9M as of Q2 2026.
  • Woodline Partners bought 259,280 Supernus Pharmaceuticals shares in Q2 2026, an estimated $12.5M.
  • Supernus Pharmaceuticals made up 0.1% of Woodline Partners's portfolio in Q2 2026, its #264 holding.
  • Woodline Partners first reported a position in Supernus Pharmaceuticals in Q3 2021 and has held it in 12 quarters since.
  • Woodline Partners's Supernus Pharmaceuticals position peaked at $60.4M in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.